Peptide PMS-001 for memory in moderate to severe dementia
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether a peptide called PMS-001 can help improve long-term memory in people with moderate to severe dementia. It is designed for adults aged 60–80 who have significant memory problems and want to explore a new potential treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 80 years old.
- You have moderate to severe dementia (confirmed by a doctor's assessment).
- You do not have other brain conditions like Parkinson's disease, stroke, or epilepsy.
- You do not have untreated thyroid problems, anemia, or vitamin B12 deficiency.
- You are not currently taking strong psychiatric medications or have a history of substance abuse.
- You do not have allergies to multiple medications, foods, or pollen (except mild seasonal allergies).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment made from stem cells (called secretome) to see if it can help people with moderate dementia. It's for patients who are generally stable and have a caregiver to support them.
This study looks at how well people with Alzheimer’s disease (AD) or mild cognitive impairment (MCI) perform on standardized memory/brain tests. It may help researchers understand changes over time, and whether certain types of brain signals or test results track with the condition.
This trial studies a non-medication (non-drug) program to improve memory and daily thinking in people with mild cognitive impairment or mild Alzheimer’s disease. It may help by supporting brain function and monitoring symptoms over time.
This trial tests a new medication called RP902 to see if it can safely help people with mild cognitive impairment—the early stage of memory and thinking problems that may lead to dementia. Researchers will measure how well it works and monitor for side effects.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This trial tests an investigational drug called Neuroaid II (MLC901) for people with mild to moderate Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Hear when a new Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.